Earnings Call Intelligence Subscribe
Home › Call Sheets › GEHC › Q4'25
Call sheet · Q4'25

GE HealthCare Technologies (GEHC)

Q4'25 earnings call · held February 4, 2026 · compared with the Q3'25 call · management-credibility review
10/12
Disclosure score
2 medium, 4 low flags
Financial quality
Bottom line
The sleeper story is service revenue quietly becoming the margin engine through enterprise deals and higher capture rates on sophisticated new products. While everyone focuses on the obvious Florcado acceleration (220 weekly doses, 95% delivery reliability), the real constraint is regulatory approval timing for nine major product launches that management admits prevents order taking until cleared. Arduini's quote 'until we have those approvals, we can't take an order' creates binary H1 2026 setup risk despite record backlog. The tariff recovery narrative is real but overshadows the emerging recurring revenue transformation. My view changes if service capture rates don't expand with new product launches or if regulatory approvals slip past midyear, undermining the 2027 revenue acceleration story.

The 30-second version

  • The sleeper story: Service revenue with enterprise deals is quietly becoming the margin expansion engine
  • Florcado finally hitting stride but they buried the lead on weekly dose acceleration
  • New product tsunami coming but orders recognition timing creates 2026 setup risk

What changed this quarter

MetricQ3'25Q4'25Change
Organic Revenue Growth4.0% (Q3 2025)4.8% (Q4 2025)+80 bps acceleration vs Q3
Adjusted EBIT Margin14.8% (Q3 2025)16.7% (Q4 2025)+190 bps sequential expansion
Adjusted EPS$1.07 (Q3 2025)$1.44 (Q4 2025)+35% sequential jump
Free Cash Flow$483M (Q3 2025)$916M (Q4 2025)+90% sequential surge
Orders Growth6% (Q3 2025)2% (Q4 2025)-400 bps deceleration
Backlog$21.2B (Q3 2025)$21.8B (Q4 2025)+$600M sequential, +$2B YoY
Imaging Organic Revenue4% (Q3 2025)5.3% (Q4 2025)+130 bps acceleration
PDX Organic Revenue10% (Q3 2025)12.7% (Q4 2025)+270 bps acceleration
AVS Organic Revenue6% (Q3 2025)4.2% (Q4 2025)-180 bps deceleration
PCS Organic Revenue-7% (Q3 2025)-1.1% (Q4 2025)+590 bps improvement from product hold recovery

Accountability tracked

8 new promises made4 narrative shifts flagged7 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full GEHC Q4'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.